Business Description
Amicus Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US03152W1099
Share Class Description:
FOLD: Ordinary SharesCompare
Compare
Traded in other countries / regions
FOLD.USAAM6.Germany0HF9.UKFOLD.Mexico IPO Date
2007-05-31Description
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.64 | |||||
| Equity-to-Asset | 0.21 | |||||
| Debt-to-Equity | 2.78 | |||||
| Debt-to-EBITDA | -4.83 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -1.23 | |||||
| Beneish M-Score | -2.58 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.3 | |||||
| 3-Year EBITDA Growth Rate | 30.7 | |||||
| 3-Year EPS without NRI Growth Rate | 23.4 | |||||
| 3-Year FCF Growth Rate | 34.3 | |||||
| 3-Year Book Growth Rate | -20.7 | |||||
| Future 3-5Y Total Revenue Growth Rate | 33.51 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.73 | |||||
| 9-Day RSI | 28.04 | |||||
| 14-Day RSI | 31.08 | |||||
| 6-1 Month Momentum % | 6.85 | |||||
| 12-1 Month Momentum % | -0.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.88 | |||||
| Quick Ratio | 2.52 | |||||
| Cash Ratio | 1.71 | |||||
| Days Inventory | 427.98 | |||||
| Days Sales Outstanding | 65.63 | |||||
| Days Payable | 180.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.9 | |||||
| Shareholder Yield % | -3 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 90.65 | |||||
| Operating Margin % | -18.4 | |||||
| Net Margin % | -37.96 | |||||
| FCF Margin % | -19.16 | |||||
| ROE % | -120.19 | |||||
| ROA % | -20.5 | |||||
| ROIC % | -22.26 | |||||
| ROC (Joel Greenblatt) % | -133.69 | |||||
| ROCE % | -17.1 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.51 | |||||
| PB Ratio | 18.49 | |||||
| EV-to-EBIT | -32.74 | |||||
| EV-to-Forward-EBIT | 84.54 | |||||
| EV-to-EBITDA | -35.54 | |||||
| EV-to-Forward-EBITDA | 66.11 | |||||
| EV-to-Revenue | 8.19 | |||||
| EV-to-Forward-Revenue | 5.97 | |||||
| EV-to-FCF | -42.76 | |||||
| Earnings Yield (Greenblatt) % | -3.05 | |||||
| FCF Yield % | -2.55 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FOLD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Amicus Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 399.356 | ||
| EPS (TTM) ($) | -0.51 | ||
| Beta | 0.6 | ||
| Volatility % | 39.46 | ||
| 14-Day RSI | 31.08 | ||
| 14-Day ATR ($) | 0.373301 | ||
| 20-Day SMA ($) | 11.046 | ||
| 12-1 Month Momentum % | -0.09 | ||
| 52-Week Range ($) | 9.7 - 14.57 | ||
| Shares Outstanding (Mil) | 296.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Amicus Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Amicus Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Amicus Therapeutics Inc Frequently Asked Questions
What is Amicus Therapeutics Inc(FOLD)'s stock price today?
The current price of FOLD is $10.17. The 52 week high of FOLD is $14.57 and 52 week low is $9.70.
When is next earnings date of Amicus Therapeutics Inc(FOLD)?
The next earnings date of Amicus Therapeutics Inc(FOLD) is 2024-05-10 Est..
Does Amicus Therapeutics Inc(FOLD) pay dividends? If so, how much?
Amicus Therapeutics Inc(FOLD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers